Log In Sign up
The largest database of trusted experimental protocols

Taqman 48 system

Manufactured by Roche
Visit Supplier
Sourced in United States

The Taqman-48 system is a Real-time PCR instrument designed for gene expression analysis and nucleic acid quantification. It features 48 reaction wells and supports multiplex detection of up to five targets simultaneously. The system utilizes TaqMan technology for reliable and sensitive nucleic acid detection and quantification.

Automatically generated - may contain errors

Lab products found in correlation

Hiv 1 kit v 2, by Roche (2 mentions) Nod scid il2rγc nsg mice, by Jackson ImmunoResearch (2 mentions)

2 protocols using taqman 48 system

1

Humanized Mouse Model for HIV-1 Challenge

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Male 6–8-week-old NOD/SCID/IL2Rγc−/− (NSG) mice (Jackson Labs, Bar Harbor, ME, USA) were injected intramuscularly with NMCAB or CAB LAP at 45 mg CAB equivalents/kg. Eleven days after nanoformulation treatments, mice were reconstituted by intraperitoneal injection with 25 × 106 human peripheral blood lymphocytes (PBL) obtained by leukapheresis and centrifugal elutriation. Eleven days after reconstitution, mice were challenged with 104 50% tissue culture infectious dose (TCID50) HIV-1ADA by intraperitoneal injections. Mice were sacrificed 10 days after viral challenge. The experimental timeline is shown in Fig. 7A. Peripheral blood was collected at days 10 (prior to PBL reconstitution), 21 (prior to HIV-1 challenge), and 32 (10 days post HIV-1 challenge) for flow cytometry analysis of human pan-CD45, CD3, CD4 and CD8 immune markers [38 (link)]. Plasma was collected via centrifugation at 2000 × g for 5 min for drug quantitation by UPLC-MS/MS. HIV-1 RNA was analyzed in day 32 plasma samples using the Roche Amplicor and Taqman-48 system with HIV-1 kit V 2.0 according to the manufacturer’s instructions (Roche Diagnostics, Indianapolis, USA). Tissues were collected for CAB concentrations by UPLC/MS/MS, viral RNA and DNA quantitation by semi-nested real-time PCR [39 (link)], and immunohistochemical staining for HIV-1p24 antigen as described previously [40 (link)].
Zhou T., Su H., Dash P., Lin Z., Shetty B.L., Kocher T., Szlachetka A., Lamberty B., Fox H.S., Poluektova L., Gorantla S., McMillan J., Gautam N., Mosley R.L., Alnouti Y., Edagwa B, & Gendelman H.E. (2017). Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 151, 53-65.
+ Open protocol
+ Expand
2

Humanized Mouse Model for HIV-1 Challenge

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Male 6–8-week-old NOD/SCID/IL2Rγc−/− (NSG) mice (Jackson Labs, Bar Harbor, ME, USA) were injected intramuscularly with NMCAB or CAB LAP at 45 mg CAB equivalents/kg. Eleven days after nanoformulation treatments, mice were reconstituted by intraperitoneal injection with 25 × 106 human peripheral blood lymphocytes (PBL) obtained by leukapheresis and centrifugal elutriation. Eleven days after reconstitution, mice were challenged with 104 50% tissue culture infectious dose (TCID50) HIV-1ADA by intraperitoneal injections. Mice were sacrificed 10 days after viral challenge. The experimental timeline is shown in Fig. 7A. Peripheral blood was collected at days 10 (prior to PBL reconstitution), 21 (prior to HIV-1 challenge), and 32 (10 days post HIV-1 challenge) for flow cytometry analysis of human pan-CD45, CD3, CD4 and CD8 immune markers [38 (link)]. Plasma was collected via centrifugation at 2000 × g for 5 min for drug quantitation by UPLC-MS/MS. HIV-1 RNA was analyzed in day 32 plasma samples using the Roche Amplicor and Taqman-48 system with HIV-1 kit V 2.0 according to the manufacturer’s instructions (Roche Diagnostics, Indianapolis, USA). Tissues were collected for CAB concentrations by UPLC/MS/MS, viral RNA and DNA quantitation by semi-nested real-time PCR [39 (link)], and immunohistochemical staining for HIV-1p24 antigen as described previously [40 (link)].
Zhou T., Su H., Dash P., Lin Z., Shetty B.L., Kocher T., Szlachetka A., Lamberty B., Fox H.S., Poluektova L., Gorantla S., McMillan J., Gautam N., Mosley R.L., Alnouti Y., Edagwa B, & Gendelman H.E. (2017). Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 151, 53-65.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!